Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you follow Rapid Micro Biosystems (RPID), you’re not just tracking another life-sciences company—you’re monitoring how quickly the pharmaceutical world adopts automated microbial quality control. Investors typically open a filing searching for answers like “Where can I find Rapid Micro Biosystems’ quarterly earnings report 10-Q filing?” or “What do Rapid Micro Biosystems insider trading Form 4 transactions reveal about Growth Direct demand?” We bring every disclosure into one streamlined view.
Stock Titan’s AI reads each 10-K, 10-Q, 8-K and immediately highlights the numbers that matter: unit placements, consumables revenue, R&D outlays, and regulatory commentary. Instead of wading through dense technical language, you’ll see concise plain-English explanations—perfect for anyone Googling “Rapid Micro Biosystems SEC filings explained simply” or “understanding Rapid Micro Biosystems SEC documents with AI.”
Need specific data fast? Use our real-time alerts for Rapid Micro Biosystems Form 4 insider transactions: the moment an executive buys or sells, you’ll receive context and trend analysis. Our coverage also includes:
- 10-K annual report sections on market adoption, simplified for quick scans—ideal for “Rapid Micro Biosystems annual report 10-K simplified” queries.
- 10-Q earnings report breakouts of consumable gross margin—answering searches for “Rapid Micro Biosystems earnings report filing analysis.”
- 8-K material events explained in minutes, from FDA updates to major customer wins.
- Proxy statement executive compensation summaries, tying pay packages to Growth Direct milestones.
With comprehensive coverage, real-time EDGAR updates, and AI-powered summaries, our filings hub turns Rapid Micro Biosystems’ complex disclosures into practical insights you can act on today.
Marvell Technology, Inc. (MRVL) has filed a Form 144 indicating that insider Panteha Dixon intends to sell 1,273 common shares through Morgan Stanley Smith Barney on or about 15 July 2025. The shares have an aggregate market value of $93,794.64, representing roughly 0.00015% of the company’s 862.2 million shares outstanding—an immaterial fraction at the corporate level. The filing also discloses that Dixon sold 3,808 shares over the prior three months for total proceeds of roughly $252 thousand. No Rule 10b5-1 trading plan adoption date is listed, and the filer affirms no knowledge of undisclosed material information. Overall, this appears to be routine, small-scale insider profit-taking rather than a transaction likely to influence Marvell’s fundamental outlook.
Rapid Micro Biosystems, Inc. (RPID) filed a LIVE Form 144 indicating that shareholder Robert G. Spignesi intends to sell up to 11,881 Class A shares through Fidelity Brokerage Services on or about 14 July 2025. At the disclosed aggregate market value of $39,480.56, the transaction equates to roughly 0.03 % of the company’s 39,332,172 shares outstanding, signalling minimal dilution.
The shares were acquired on 11 July 2025 via restricted-stock vesting and are therefore compensation related. The filing also details four prior sales by the same holder between 8-11 July 2025 totalling 45,562 shares for gross proceeds of about $156,780. Under Rule 144, the filer certifies that no non-public material adverse information is known.
- Class of security: Class A common
- Broker: Fidelity Brokerage Services LLC, Smithfield, RI
- Proposed exchange: NASDAQ
- Recent selling cadence: ~11–12 k shares per day during 8-11 July 2025
While the absolute dollar amount is modest, the consecutive insider sales may be monitored by investors as a sentiment indicator.
Rapid Micro Biosystems, Inc. (symbol: RPID) has filed a Form 144 disclosing an insider’s intent to sell shares. Robert G. Spignesi plans to dispose of 11,874 Class A shares on or about 11 July 2025 via NASDAQ, using Fidelity Brokerage Services as broker. At the reference price in the notice, the sale is valued at roughly $39,498.86. The filing cites the shares as recently vested restricted stock received as compensation on 10 July 2025.
The document also lists three prior transactions by the same insider between 8-10 July 2025 totaling 33,688 shares for gross proceeds of $116,981.01. With 39,332,172 shares outstanding, the forthcoming sale represents about 0.03 % of the company’s float, indicating a routine liquidity event rather than a material ownership change.
Rapid Micro Biosystems, Inc. (RPID) – CEO Form 4 filing dated 10 Jul 2025
President & CEO Robert G. Spignesi Jr. reported a series of transactions from 8-10 Jul 2025 involving performance-based restricted stock units (PRSUs):
- Vesting/Exercise (Code M): 75,433 Class A shares were issued at a $0 exercise price after performance criteria were met (25,144 on 7/08, 25,144 on 7/09, 25,145 on 7/10).
- Tax-related sales (Code S): 33,688 shares were sold to cover withholding obligations at prices between $3.398-$3.513.
- Net share increase: The CEO’s direct holdings rose by approximately 41,745 shares to 944,015 shares after the transactions. This total includes 29,904 shares previously purchased under the company’s employee stock purchase plan (3/14/2025).
No derivative securities remain outstanding from these transactions. Because the sales were explicitly to satisfy tax obligations, the actions are generally viewed as neutral to modestly positive—they do not signal discretionary selling pressure, while the net increase modestly aligns the CEO’s interests with shareholders.
Sequans Communications S.A. (NYSE: SQNS) has filed a Form 144 notice for the proposed sale of restricted securities. The filer intends to sell 13,000 American Depositary Shares (ADS) through Morgan Stanley Smith Barney LLC on or about 10 July 2025. At the filing date, the aggregate market value of the planned sale is $26,910, implying a price of roughly $2.07 per ADS. The ADSs to be sold represent approximately 0.05 % of the company’s 25.39 million shares outstanding, indicating a small, non-dilutive transaction. No additional share sales were reported by the filer during the past three months, and the securities were originally acquired on 31 December 2021 via a private transaction with the issuer. The Form 144 contains the standard representation that the filer is not in possession of undisclosed material adverse information.
The filing is a routine disclosure required under SEC Rule 144 when an affiliate or insider plans to sell restricted or control securities. Given the limited share count and modest dollar value, the transaction is unlikely to materially affect SQNS’s float or trading liquidity but may offer a minor directional signal about the seller’s intentions.
On July 9, 2025, Kite Realty Group Trust (NYSE: KRG) submitted a Form 4 reporting that director Victor J. Coleman acquired 524 common share units on July 1, 2025. The units were recorded at a price of $0, indicating a routine equity grant awarded as part of director compensation. After the transaction, Coleman’s direct ownership stands at 96,425 KRG shares. No derivative securities were involved, and there is no indication of open-market buying or selling. The filing reflects a modest, non-cash increase in insider holdings and is not likely to materially affect Kite Realty Group’s share structure or market outlook.
On 7 July 2025, W. P. Carey Inc. (NYSE: WPC) entered into an underwriting agreement with Wells Fargo Securities, BofA Securities and Scotia Capital (USA) Inc. for a public offering of $400 million aggregate principal amount of 4.650% Senior Notes due 2030. The notes are expected to settle on 10 July 2025 under the company’s automatic shelf registration (File No. 333-286885).
The company will apply the net proceeds to repay a portion of borrowings outstanding under its $2.0 billion unsecured revolving credit facility and for other general corporate purposes. The underwriting agreement contains customary representations, warranties, covenants and indemnification provisions. A pricing press release was simultaneously issued (Exhibit 99.1).
- Issue Size: $400 million
- Coupon: 4.650%
- Maturity: 2030
- Expected Closing: 10 July 2025
- Use of Proceeds: Debt repayment & general corporate
No earnings figures or other financial performance data were disclosed in this Form 8-K.